Novartis has agreed to acquire UK-based Myricx Bio for up to $1.5bn, adding a preclinical antibody-drug conjugate platform built around a novel payload class for solid tumours.
https://european-biotechnology.com/wp-content/uploads/2026/07/novartis-logo-banting-1-vertical-scaled.jpg20572560Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-07-06 10:20:032026-07-06 10:20:03Novartis buys UK ADC biotech Myricx Bio in up to $1.5bn deal
Roche’s Genentech has signed an oncology research deal with Astex, hoping the UK-based biotech will hit the jackpot again after a similar tie-up with rival Novartis produced the blockbuster breast cancer drug Kisqali.
https://european-biotechnology.com/wp-content/uploads/2026/07/angiola-harry-SJCalEw-1LM-unsplash-scaled.jpg17022560Richard Staines/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngRichard Staines2026-07-06 09:10:002026-07-06 13:10:04Genentech signs $490m breast cancer deal with Astex
SLAS Europe 2026 in Vienna brought together over 1,500 delegates for three days of innovation and collaboration. As we look ahead, join us at upcoming Meet-Ups in Leiden and Tübingen, and mark your calendars for SLAS2027 in San Diego, California.
https://european-biotechnology.com/wp-content/uploads/2026/06/Seite-55_ebm226-asso-slasslasEU_day1_highlights-16.jpg540960Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2026-07-06 08:00:192026-06-29 08:29:55SLAS Europe 2026 – Recap and Outlook
With the appointment of Russell Thomas as Chief Scientific Officer, Symeres and Axxam are further strengthening their strategic collaboration. The goal is to provide pharmaceutical and biotechnology companies with an integrated platform for drug discovery and development from a single source.
https://european-biotechnology.com/wp-content/uploads/2026/07/EB.com_Russell-thomas.jpg772687Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2026-07-03 13:24:382026-07-03 13:24:38One CSO for two companies
AstraZeneca has signed another deal with China’s CSPC Pharmaceutical Group, this time to discover and develop siRNA drug candidates for kidney diseases.
Spanish epigenetics biotech Oryzon Genomics has raised €12m in a capital increase and signed a financing agreement with COFIDES that could add another €25m in future share subscriptions.
https://european-biotechnology.com/wp-content/uploads/2026/07/antonio-feregrino-L57L1mlKoM8-unsplash-scaled.jpg19202560Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-07-02 16:46:092026-07-02 16:46:09Oryzon raises €12m to push AML and CNS pipeline
By appointing Olav Hellebø as Chief Executive Officer, biotechnology company Exonate Ltd. aims to accelerate the clinical development of its lead candidate for diabetic eye disease.
https://european-biotechnology.com/wp-content/uploads/2026/07/EB.com_Olav_Hellebo_neu.jpeg16901507Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2026-07-02 15:12:392026-07-02 15:16:11Experienced CEO takes over
Abivax has raised $920m (€807m) in gross proceeds through a US public offering, only days after new obefazimod data helped calm investor concerns over the drug’s safety profile in ulcerative colitis.
https://european-biotechnology.com/wp-content/uploads/2026/07/wesley-tingey-ak5yDsh1kDQ-unsplash-scaled.jpg17072560Joachim Eeckhout/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngJoachim Eeckhout2026-07-02 09:33:252026-07-02 09:33:25Abivax cashes in on investor enthusiasm with €807m raise
Swedish biotech AlzeCure Pharma has licensed global rights to its NeuroRestore platform, including lead Alzheimer’s candidate ACD856, to Danish biotech QuantumCell ApS in a deal worth more than $2.2bn, excluding royalties.
Novartis buys UK ADC biotech Myricx Bio in up to $1.5bn deal
Latest NewsNovartis has agreed to acquire UK-based Myricx Bio for up to $1.5bn, adding a preclinical antibody-drug conjugate platform built around a novel payload class for solid tumours.
Genentech signs $490m breast cancer deal with Astex
Latest NewsRoche’s Genentech has signed an oncology research deal with Astex, hoping the UK-based biotech will hit the jackpot again after a similar tie-up with rival Novartis produced the blockbuster breast cancer drug Kisqali.
SLAS Europe 2026 – Recap and Outlook
AssociationsSLAS Europe 2026 in Vienna brought together over 1,500 delegates for three days of innovation and collaboration. As we look ahead, join us at upcoming Meet-Ups in Leiden and Tübingen, and mark your calendars for SLAS2027 in San Diego, California.
One CSO for two companies
AppointmentsWith the appointment of Russell Thomas as Chief Scientific Officer, Symeres and Axxam are further strengthening their strategic collaboration. The goal is to provide pharmaceutical and biotechnology companies with an integrated platform for drug discovery and development from a single source.
AstraZeneca returns to CSPC with $1.77bn kidney deal
Latest NewsAstraZeneca has signed another deal with China’s CSPC Pharmaceutical Group, this time to discover and develop siRNA drug candidates for kidney diseases.
Oryzon raises €12m to push AML and CNS pipeline
Latest NewsSpanish epigenetics biotech Oryzon Genomics has raised €12m in a capital increase and signed a financing agreement with COFIDES that could add another €25m in future share subscriptions.
Experienced CEO takes over
AppointmentsBy appointing Olav Hellebø as Chief Executive Officer, biotechnology company Exonate Ltd. aims to accelerate the clinical development of its lead candidate for diabetic eye disease.
Telum raises €18M to push phage-derived antimicrobials toward clinic
Latest NewsSpanish biotech Telum Therapeutics has raised €18 million in Series A financing to move its lead antimicrobial programme toward clinical development.
Abivax cashes in on investor enthusiasm with €807m raise
Latest NewsAbivax has raised $920m (€807m) in gross proceeds through a US public offering, only days after new obefazimod data helped calm investor concerns over the drug’s safety profile in ulcerative colitis.
AlzeCure licenses Alzheimer’s asset to QuantumCell in $2.2bn deal
Latest NewsSwedish biotech AlzeCure Pharma has licensed global rights to its NeuroRestore platform, including lead Alzheimer’s candidate ACD856, to Danish biotech QuantumCell ApS in a deal worth more than $2.2bn, excluding royalties.